Kenvue Inc. (KVUE)
Automate Your Wheel Strategy on KVUE
With Tiblio's Option Bot, you can configure your own wheel strategy including KVUE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KVUE
- Rev/Share 7.9948
- Book/Share 5.2524
- PB 4.0668
- Debt/Equity 0.8692
- CurrentRatio 0.8566
- ROIC 0.08
- MktCap 41009275464.0
- FreeCF/Share 0.7576
- PFCF 28.2823
- PE 38.715
- Debt/Assets 0.3328
- DivYield 0.0384
- ROE 0.1042
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KVUE | Redburn Atlantic | -- | Neutral | -- | $23.5 | April 10, 2025 |
| Initiation | KVUE | Evercore ISI | -- | In-line | -- | $25 | March 24, 2025 |
| Upgrade | KVUE | Piper Sandler | Neutral | Overweight | $21 | $26 | Jan. 6, 2025 |
| Downgrade | KVUE | Deutsche Bank | Buy | Hold | $25 | $24 | Dec. 12, 2024 |
| Initiation | KVUE | Jefferies | -- | Buy | -- | $27 | Sept. 24, 2024 |
| Downgrade | KVUE | RBC Capital Mkts | Outperform | Sector Perform | -- | $24 | Sept. 24, 2024 |
News
Kenvue takeover speculation heats up ahead of M&A window
Published: June 16, 2025 by: Proactive Investors
Sentiment: Positive
Kenvue Inc (NYSE:KVUE) is again at the center of takeover speculation as the August expiration of its post–spin-off tax agreement with Johnson & Johnson (NYSE:JNJ) approaches, potentially clearing the way for a sale. Despite concentration and uneven performance, Kenvue's brand lineup is attractive, according to analysts at Jefferies.
Read More
Kenvue considering sale of skin and beauty brands to streamline portfolio: report
Published: June 13, 2025 by: Proactive Investors
Sentiment: Neutral
Kenvue Inc (NYSE:KVUE), the consumer health company spun off from Johnson & Johnson (NYSE:JNJ) in 2023, is considering selling a selection of its smaller skin health and beauty brands to streamline this segment and refocus on its core products, according to a Reuters report. The report, which cited four people with knowledge of the matter, is considering the sale of brands such as Clean & Clear, Maui Moisture, Neostrata, its German baby care brand Bebe, and Japanese brand Dr.Ci:Labo.
Read More
Kenvue: Steady Consumer Health Play; Initiate With 'Buy'
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Positive
I initiate Kenvue with a 'Buy' rating and a $26 fair value, citing its iconic brands and steady dividend appeal. Kenvue's global operations, diversified product lines, and strong R&D enable resilience and ongoing margin expansion through cost efficiencies. Short-term headwinds from China destocking and tariffs are manageable, with long-term organic growth expected to normalize at 4.5%.
Read More
Kenvue Debuts on Fortune 500 List
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science.
Read More
Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Thibaut Mongon, Chief Executive Officer, Amit Banati, Chief Financial Officer, and Carlton Lawson, Group President, Europe, Middle East and Africa & Latin America will participate in a fireside chat on Tuesday, June 3, 2025, at 6:00 a.m.
Read More
Moody's U.S. Debt Downgrade: Stocks Poised To Benefit
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
Corporations play a vital and often benevolent role in capitalist societies, supporting economic growth and innovation with more conservative balance sheets than their governments. Microsoft, Apple and Johnson & Johnson hold Moody's highest credit rating of Aaa, reflecting exceptional financial strength and stability. Alphabet and Berkshire Hathaway are rated Aa2 by Moody's, indicating very high credit quality, just below the top tier.
Read More
Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Kenvue, Inc. (NYSE:KVUE ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Sofya Tsinis - Head of Investor Relations Thibaut Mongon - Chief Executive Officer and Director Paul Ruh - Chief Financial Officer Conference Call Participants Bonnie Herzog - Goldman Sachs Peter Grom - UBS Andrea Teixeira - J.P. Morgan Anna Lizzul - Bank of America Keith Davis - Jefferies Nik Modi - RBC Capital Markets Filippo Falorni - Citi Javier Escalante - Evercore ISI Alec Legg - Canaccord Genuity Steve Powers - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Operator Hello, and welcome to …
Read More
Compared to Estimates, Kenvue (KVUE) Q1 Earnings: A Look at Key Metrics
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Kenvue (KVUE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Kenvue Boosts 2025 Sales Growth View
Published: May 08, 2025 by: WSJ
Sentiment: Positive
The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth projection for the year, while warning that foreign exchange would weigh on adjusted earnings.
Read More
Kenvue (KVUE) Beats Q1 Earnings and Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Kenvue (KVUE) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.28 per share a year ago.
Read More
Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Sales Outlook
Published: May 08, 2025 by: Investopedia
Sentiment: Positive
Shares of Kenvue (KVUE) rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates.
Read More
Kenvue stock climbs as second quarter comes in ahead of forecasts
Published: May 08, 2025 by: Proactive Investors
Sentiment: Positive
Consumer brands firm Kenvue Inc (NYSE:KVUE) traded on the front foot in Thursday's early deals, as its second quarter beat expectations (but, fell short in year-over-year comparatives). Net sales totalled $3.74 billion in Kenvue's first quarter, exceeding the consensus forecast of $3.68 billion whilst 3.9% lower than last year's digit.
Read More
Kenvue first-quarter results beat estimates on strength in self care unit
Published: May 08, 2025 by: Reuters
Sentiment: Positive
Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self-care products including cough and cold medicines Tylenol and Benadryl helped offset a fall in demand for its skin health and beauty products.
Read More
Kenvue Announces Chief Financial Officer Transition
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a.
Read More
Buy 3 "Safer" Dividend Kings Of 25 From May's 55
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
The May collection of Dividend Kings grew to 55, with Automatic Data Processing and RLI Corporation joining, despite two companies dropping off for not increasing dividends. Six top-yield Dividend Kings, including Altria and Canadian Utilities, are now fairly priced, with annual dividends from $1K investments exceeding their single-share prices. Analysts predict net gains of 14.7% to 56.86% for the top ten Dividend Kings by yield for the coming year, based on target prices. Among the 55 Dividend Kings, 16 show negative free cash flow margins, making them cash-poor and unsafe for investment.
Read More
Kenvue (KVUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Kenvue (KVUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Two Stocks To Consider During Market Unrest To Provide Income Stability
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Positive
Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price stability and a 3.59% dividend yield, despite potential headwinds from tariffs and economic slowdown. Altria Group, with its 7% yield and Dividend King status, provides stability and potential upside during economic uncertainty, leveraging its pricing power and recession-proof products.
Read More
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
Published: February 21, 2025 by: The Motley Fool
Sentiment: Neutral
Kenvue (KVUE 0.54%) stock is down since completing its spin-off from Johnson & Johnson (JNJ 1.13%) in August 2023. But with more than a year of results now in the books, investors have had time to acclimate to Kenvue as an independent entity.
Read More
Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
Kenvue, spun off from Johnson & Johnson, shows potential as a solid dividend stock post-2025 despite current economic challenges and recent earnings misses. The company boasts strong brands like Tylenol and Listerine, and management's cost-cutting initiatives aim to save $350 million by 2026. Kenvue's valuation and growth prospects make it attractive for long-term dividend investors, but cash flow headwinds warrant a hold rating for now.
Read More
Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 19, 2025, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. i.
Read More
Kenvue: An Intriguing Turnaround
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand portfolio, including Tylenol and Band-Aid, suggests potential for a turnaround, supported by activist investor Starboard Value. Execution issues, external factors, and potential structural changes have impacted Kenvue's performance, but improvements in marketing and management could drive future growth.
Read More
About Kenvue Inc. (KVUE)
- IPO Date 2023-05-04
- Website https://www.kenvue.com
- Industry Household & Personal Products
- CEO Mr. Thibaut Mongon
- Employees 22000